DOI: https://doi.org/10.71317/kjard.2.6.2026.273

The Kashmir Journal of Academic Research and Development

Journal homepage: https://rjsaonline.org/index.php/KJARD

Phytochemical Combination Therapy for Managing Diabetes-Associated Metabolic Dysfunction and Cognitive Decline.

Hafiz Muhammad Umer Farooq
Department of Biosciences, Faculty of Veterinary Sciences, Bahauddin Zakariya University, Multan, Pakistan
Email: hmumerfarooq@bzu.edu.pk

Muhammad Usman
Department of Biosciences, Faculty of Veterinary Sciences, Bahauddin Zakariya University, Multan, Pakistan
Email: muhammadusman@bzu.edu.pk

Muhammad Shoaib Azeem
Department of Livestock and poultry Production, FVS BZU

Ghulam Shabbir
PhD Scholar, University of Agriculture, Faisalabad

Mishkwat Hameed
BSc Student, Capital University of Science and Technology.

ARTICLE INFO

Received:
April 21, 2026
Revised:
May 04, 2026
Accepted:
May 18, 2026
Available Online:
June 03, 2026

Keywords:
curcumin; quercetin; diabetes mellitus; metabolic dysfunction; cognitive decline; combination therapy; phytochemicals; neuroprotection

Corresponding Author:
hmumerfarooq@bzu.edu.pk

ABSTRACT

Diabetes mellitus is no longer viewed only as a disorder of glucose regulation. Long-standing hyperglycemia and insulin resistance set off a chain of oxidative stress, chronic inflammation and lipid disturbance that damages tissues well beyond the pancreas and the vasculature. Over the past decade, a growing body of evidence has shown that these same disturbances reach the brain, contributing to memory loss, slowed thinking and behavioral changes that are now commonly grouped under the heading of diabetes-associated cognitive decline. Because metabolic dysfunction and cognitive impairment in diabetes share overlapping molecular pathways, including AMPK, NF-κB, Nrf2, PI3K/Akt and acetylcholinesterase-related signaling, a therapy that can act on more than one of these targets at once has obvious appeal. This review brings together the current preclinical and early clinical evidence on curcumin and quercetin, two widely studied dietary phytochemicals, and examines the rationale for using them together rather than alone. Curcumin is best known for its anti-inflammatory and antioxidant activity, while quercetin has a stronger track record in improving insulin sensitivity and glucose handling. When combined, the two compounds appear to act in a complementary rather than overlapping manner, producing effects on glycemic control, oxidative markers and cognitive performance that are generally more consistent than either compound gives on its own. The review also looks at the practical barriers that have kept this approach from moving further into the clinic, particularly poor oral bioavailability, and discusses the delivery strategies, including phytosomes and nanoparticle systems, that are being tested to address this problem. The available data support combination phytochemical therapy as a promising, low-toxicity adjunct approach for diabetes-associated metabolic and cognitive dysfunction, though well-designed human trials with standardized dosing are still needed before firm clinical recommendations can be made.

Introduction

Diabetes mellitus has grown from a manageable chronic condition into one of the defining health burdens of this century. The International Diabetes Federation now estimates that roughly 11 percent of adults worldwide, close to 1 in 9, are living with diabetes, and more than 4 in 10 of these individuals remain undiagnosed [1,2]. Projections suggest that by 2050 the number of affected adults could reach 853 million, an increase of close to 46 percent over current figures [2]. The burden is not evenly distributed. South Asia alone accounts for a large share of the global total, with India contributing an estimated 89 million cases and many patients in the region achieving poor glycaemic control even while on treatment [4]. Type 2 diabetes makes up more than 90 percent of all cases and is closely tied to diet, physical inactivity and rising rates of obesity [2].

For many years, the clinical conversation around diabetes complications focused mainly on the eyes, kidneys, nerves and heart. Cognitive and behavioral changes received comparatively little attention, partly because their onset is gradual and easy to attribute to normal aging. That picture has shifted. A substantial number of studies over the last fifteen years have linked chronic hyperglycemia, insulin resistance and vascular damage to measurable declines in memory, attention and executive function, and to an increased risk of vascular dementia and Alzheimer's disease in people with long-standing diabetes [3,6,12,13]. Some researchers now refer to this cluster of brain changes as "type 3 diabetes," reflecting how closely insulin signaling in the brain mirrors that in peripheral tissue.

The pathways responsible for metabolic dysfunction and those responsible for cognitive decline in diabetes are not separate systems running in parallel. They overlap. Oxidative stress, low-grade systemic inflammation and impaired insulin signaling feed into both processes, and key regulatory proteins such as AMP-activated protein kinase (AMPK), nuclear factor kappa-B (NF-κB), nuclear factor erythroid 2-related factor 2 (Nrf2), the PI3K/Akt axis and acetylcholinesterase (AChE) appear repeatedly in studies of both diabetic metabolic complications and diabetic cognitive impairment [6,7,8,11,13]. This overlap is the central reason this review focuses on combination phytochemical therapy rather than single-compound treatment. If one intervention can influence several of these shared nodes at once, it is reasonable to expect a broader and more durable benefit than a drug or supplement acting on only one pathway.

Curcumin and quercetin were selected as the focus of this review because they are among the most extensively studied dietary phytochemicals in both the metabolic and neuroscience literature, and because a growing number of studies have begun testing them in combination rather than isolation [17,20,21]. Curcumin, derived from turmeric (Curcuma longa), has a long history of use in traditional medicine and a well-documented capacity to reduce inflammation and oxidative damage [5,18]. Quercetin, a flavonoid abundant in onions, apples and many other plant foods, has a stronger and more consistent record of improving insulin sensitivity and glucose uptake through AMPK and PI3K/Akt signaling [7,8,9]. Individually, both compounds show real but modest and sometimes inconsistent effects in clinical settings, largely because of poor oral bioavailability. Combined, and particularly when formulated using delivery systems that improve absorption, the two compounds appear to act on a wider set of targets with fewer of the side effects associated with conventional pharmacological agents [17,20,21].

This review has three aims. First, to summarize the pathophysiology connecting diabetes-associated metabolic dysfunction with cognitive and behavioral decline, with attention to the molecular pathways shared between the two. Second, to review the preclinical and clinical evidence for curcumin, quercetin and their combination in addressing both arms of this problem. Third, to discuss the practical barriers, mainly around bioavailability and standardization, that continue to limit clinical translation, and to outline where the field is likely to move next, including nanoparticle and phytosome-based delivery systems.

Diabetes Mellitus and Metabolic Dysfunction: A Pathophysiological Overview

Type 2 diabetes develops when peripheral tissues, chiefly skeletal muscle, liver and adipose tissue, become progressively less responsive to insulin. In the early stages, the pancreas compensates by secreting more insulin, but beta-cell function tends to decline over time under the combined pressure of glucotoxicity, lipotoxicity and oxidative stress. The result is a self-reinforcing cycle: insulin resistance drives hyperglycemia, hyperglycemia damages beta cells and worsens insulin resistance, and the metabolic disturbance widens to affect lipid metabolism, blood pressure and coagulation.

At the cellular level, several interconnected mechanisms are consistently implicated. Chronic hyperglycemia increases the production of reactive oxygen species through mitochondrial overload and the polyol, hexosamine and advanced glycation end-product pathways. This oxidative burden damages proteins, lipids and DNA, and it activates NF-κB signaling, which in turn drives the release of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and interleukin-1 beta

(IL-1β) [21]. These cytokines interfere with insulin receptor signaling by promoting serine phosphorylation of insulin receptor substrate proteins, which blunts the normal tyrosine phosphorylation needed for downstream PI3K/Akt activation and GLUT4 translocation to the cell membrane [7,9].

AMPK acts as a kind of cellular energy sensor and its activity is typically reduced in insulin-resistant tissue. When active, AMPK promotes glucose uptake, fatty acid oxidation and suppression of hepatic gluconeogenesis; when suppressed, the liver continues to overproduce glucose even in the presence of high circulating insulin, worsening hyperglycemia [6,11]. Nrf2, the master regulator of the cellular antioxidant response, is also frequently downregulated in diabetic tissue, leaving cells with a reduced capacity to buffer oxidative stress through enzymes such as heme oxygenase-1, superoxide dismutase and glutathione peroxidase [11].

Dyslipidemia is a near-universal feature of type 2 diabetes and compounds the problem further. Elevated free fatty acids contribute to lipotoxicity in the liver, muscle and pancreas, and adipose tissue itself becomes a source of pro-inflammatory signaling as it becomes infiltrated with activated macrophages. Over time, this combination of hyperglycemia, chronic inflammation, oxidative stress and dyslipidemia damages the microvasculature and macrovasculature, producing the classic complications of diabetes: nephropathy, retinopathy, neuropathy and accelerated atherosclerosis.

It is worth emphasizing that none of these processes are confined to the periphery. The same oxidative and inflammatory signals that damage the kidney or the retina circulate systemically and cross, to varying degrees, the blood-brain barrier. This is the physiological bridge that connects metabolic dysfunction to the cognitive and behavioral changes discussed in the next section.

Diabetes-Associated Cognitive and Behavioral Decline

The brain is an energy-intensive organ and depends heavily on stable glucose supply and functioning insulin signaling, even though it was once assumed to be an insulin-independent tissue. Insulin receptors are in fact densely expressed in the hippocampus, a region central to memory formation, and disrupted insulin signaling in this area has been repeatedly linked to synaptic dysfunction and memory impairment in both animal models and human studies [3,12,13].

Several converging mechanisms explain how diabetes damages cognitive function over time. Chronic hyperglycemia promotes the formation of advanced glycation end-products in neural tissue, which trigger local inflammation and oxidative stress within the brain itself. Diabetic microvascular disease reduces cerebral blood flow, and in some patients this overlaps with chronic cerebral hypoperfusion, a recognized risk factor for vascular dementia. Research using combined diabetes and hypoperfusion models in rats has shown that the two conditions act synergistically to worsen cognitive outcomes, with neuroinflammation, apoptosis and pyroptosis in the hippocampus all playing a role in the resulting memory deficits [12].

Insulin resistance in the brain also has direct consequences for amyloid processing. Insulin-degrading enzyme, which normally helps clear amyloid-beta peptide, is shared between insulin metabolism and amyloid clearance. When insulin signaling is chronically elevated, as it often is in early insulin-resistant states, this enzyme becomes preferentially occupied with insulin degradation, leaving less capacity to clear amyloid-beta. This is one of several mechanistic links researchers point to when describing the overlap between diabetes and Alzheimer's disease pathology [13].

Behavioral changes associated with diabetes extend beyond memory. Anxiety-like behavior, reduced motivation, disrupted sleep architecture and mild depressive symptoms are commonly reported in both clinical populations and animal models of diabetes, and these changes tend to correlate with the severity and duration of hyperglycemia. Acetylcholinesterase activity, the enzyme responsible for breaking down the neurotransmitter acetylcholine, is frequently elevated in diabetic animal models, reducing cholinergic signaling in regions responsible for attention and memory consolidation. This is one of the reasons AChE has become a target of interest for phytochemicals being investigated for diabetes-associated cognitive decline, alongside their established roles in metabolic pathways.

Clinically, these findings matter because cognitive decline in people with diabetes is not simply an unfortunate coincidence of aging in a population that also happens to have a metabolic disorder. The relationship appears to be mechanistic and, at least partially, modifiable. This creates a rationale for interventions that address the shared upstream drivers, namely oxidative stress, inflammation and impaired insulin and AMPK signaling, rather than treating glycemic control and cognitive symptoms as unrelated problems.

Shared Molecular Mechanisms Linking Metabolic and Neurocognitive Pathways

The overlap between metabolic dysfunction and cognitive decline in diabetes is best understood not as two separate disease processes occurring in the same patient, but as two downstream expressions of a shared upstream disturbance. Figure 1 summarizes this relationship in schematic form.

Figure 1. Pathophysiological Link Between Diabetes-Associated Metabolic Dysfunction and Cognitive/Behavioral Decline



Figure 1. Pathophysiological link between diabetes-associated metabolic dysfunction and cognitive/behavioral decline, showing the shared molecular hub through which both outcomes are driven.

Five pathways recur across the literature reviewed for this article and are treated here as the primary shared targets for phytochemical intervention.

AMPK

AMPK activation improves glucose uptake in skeletal muscle, suppresses hepatic gluconeogenesis and supports mitochondrial biogenesis. In the brain, AMPK activation has been linked to improved mitochondrial function in hippocampal neurons and to protection against diabetic peripheral neuropathy through the AMPK/PGC-1α axis [6]. Both curcumin and quercetin have demonstrated AMPK-activating effects in preclinical models.

NF-κB

NF-κB is the central switch for inflammatory gene expression. Its chronic activation in diabetes drives the release of cytokines that worsen both peripheral insulin resistance and central neuroinflammation. Suppressing NF-κB signaling is one of the most consistently reported effects of curcumin across metabolic and neurological disease models [12,21].

Nrf2/ARE

The Nrf2 antioxidant response pathway helps cells cope with the oxidative burden created by chronic hyperglycemia. Nrf2 activation has been shown to protect against diabetic kidney injury through inhibition of ferroptosis, and similar antioxidant mechanisms are believed to protect neural tissue from glucose-driven oxidative damage [11].

PI3K/Akt

This pathway sits at the core of insulin signal transduction and is required for GLUT4 translocation and glucose uptake in peripheral tissue, as well as for neuronal survival and synaptic plasticity in the brain. Quercetin has a well-documented ability to enhance PI3K/Akt signaling and improve insulin-stimulated glucose uptake [8,9].

Acetylcholinesterase (AChE)

Although AChE is not a classic metabolic target, its relevance to diabetes-associated cognitive decline has made it a standard endpoint in behavioral and neurochemical studies of phytochemical treatment. Reduced AChE activity generally correlates with improved performance on memory tasks such as the Morris water maze in diabetic rodent models.

Because curcumin and quercetin do not act on an identical set of these five pathways with equal strength, using them together offers a practical way of covering more of this shared molecular territory than either compound achieves alone. This principle is explored in detail in section 6.

Phytochemicals as Therapeutic Candidates

Interest in plant-derived bioactive compounds as adjuncts or alternatives to conventional antidiabetic and neuroprotective drugs has grown steadily, driven partly by the multi-target nature of many phytochemicals and partly by their comparatively favorable safety profile. Curcumin and quercetin are two of the most extensively characterized compounds in this category, and both are supported by a large body of mechanistic, preclinical and, increasingly, clinical evidence.

Curcumin

Curcumin is the principal polyphenolic compound in turmeric and has been studied for its antidiabetic, anti-inflammatory, antioxidant and neuroprotective properties [5,18]. Network pharmacology and molecular docking studies have identified a wide array of predicted molecular targets for curcumin in diabetes, with strong interactions reported for AKT1 among other hub proteins involved in insulin signaling and inflammation [30,31].

In diabetic rodent models, curcumin has repeatedly shown the ability to lower blood glucose, improve lipid profiles and reduce markers of oxidative stress and inflammation. Its neuroprotective effects are particularly well documented in models that combine diabetes with additional cognitive insults. In one study using rats with both diabetes and chronic cerebral hypoperfusion, curcumin administration reduced hippocampal neuronal damage and improved cognitive performance, an effect linked to suppression of the TREM2/TLR4/NF-κB pathway and reduced apoptosis and pyroptosis [12]. In a separate model combining diabetes with exercise, curcumin supplementation improved glucose homeostasis and memory retention in the Morris water maze test, alongside reductions in inflammatory cytokines and markers of endoplasmic reticulum stress [15].

Despite this promising mechanistic and preclinical profile, curcumin's clinical utility has long been limited by very poor oral bioavailability, a consequence of low aqueous solubility, rapid metabolism through glucuronidation and sulfation, and fast systemic clearance. Nanoformulated curcumin, including liposomal, micellar and polymeric nanoparticle preparations, has been developed specifically to address this limitation and has shown improved pharmacokinetic behavior in recent studies, although questions remain about long-term stability and standardization across different formulations [18,22].

Quercetin

Quercetin is a flavonol widely distributed in fruits, vegetables and tea, and it has one of the more consistent evidence bases among dietary polyphenols for direct effects on glucose metabolism. In diabetic rodent models, quercetin restores insulin receptor substrate-1 and PI3K signaling, activates AMPK in the liver to reduce glycogenic enzyme activity, and promotes GLUT4 translocation to the cell membrane in skeletal muscle, collectively improving glucose uptake and lowering fasting blood glucose [7,8,9].

Beyond glycemic control, quercetin has demonstrated protective effects across several diabetic complications. It reduces ferroptosis and activates Nrf2 signaling in models of diabetic kidney disease [11], improves mitochondrial function through the AMPK/PGC-1α pathway in diabetic peripheral neuropathy [6], and shows favorable effects on liver enzymes and inflammatory markers in patients with metabolic dysfunction-associated steatotic liver disease according to a recent systematic review and meta-analysis of randomized controlled trials [10]. Network pharmacology studies exploring quercetin's role in diabetic wound healing and diabetic

nephropathy have consistently identified AKT1, TNF, PI3K-Akt signaling and inflammatory pathways as central to its mechanism of action, reinforcing the same molecular themes seen in metabolic and cognitive contexts [32,35,37].

Evidence for quercetin's direct effect on cognition in humans is more mixed than its metabolic evidence base. A large randomized trial found no significant effect of quercetin supplementation on memory, reaction time or cognitive flexibility in a general adult population [1]. This does not necessarily contradict its relevance to diabetes-associated cognitive decline specifically, since the mechanisms most likely to matter in a diabetic, insulin-resistant brain, namely AMPK activation and mitochondrial protection, may not produce a measurable benefit in metabolically healthy individuals. It does, however, argue for caution in extrapolating quercetin's cognitive benefits beyond the diabetic or metabolically compromised population in which the mechanistic rationale is strongest.

Like curcumin, quercetin suffers from limited oral bioavailability due to poor water solubility and extensive first-pass metabolism, and this has motivated similar interest in nanoparticle and phytosome-based delivery strategies, discussed further in section 9.

Rationale and Evidence for Combination Therapy

The case for combining curcumin and quercetin rests on a simple observation: the two compounds do not act on identical points within the shared molecular hub described in section 4. Curcumin's strongest and most reproducible effects are on NF-κB-mediated inflammation and oxidative stress, while quercetin's strongest effects are on insulin signaling through PI3K/Akt and on AMPK-mediated glucose handling. Figure 2 summarizes how the two compounds converge on, and diverge across, this shared set of targets.

Figure 2. Shared Molecular Targets of Curcumin and Quercetin in Metabolic and Neurocognitive Pathways



Figure 2. Shared and complementary molecular targets of curcumin and quercetin in metabolic and neurocognitive pathways.

This complementary rather than redundant mechanism of action is the pharmacological basis for expecting a combination to outperform either compound used alone, particularly across a broad set of outcome domains rather than any single measure. Direct experimental support for this idea comes from in vitro work combining curcumin, quercetin and the stilbene polydatin, which found that the combination protected cells more effectively against high-glucose-induced inflammation and oxidative stress than

any single compound tested in isolation [21]. Formulation studies combining curcumin and quercetin in phytosome-based tablets for type 2 diabetes management have likewise reported favorable in vivo outcomes when the two compounds are delivered together in a bioavailability-enhanced form [17], and nanoparticle delivery systems built specifically to co-encapsulate curcumin and quercetin have demonstrated improved intestinal absorption and enhanced antioxidant activity compared with either compound delivered alone [20].

Figure 3 presents a schematic synthesis of the directional trends reported across the studies reviewed in this article, organized by outcome domain. It is not a pooled statistical analysis of trial data, since the underlying studies differ substantially in design, dosing, species and outcome measures, and combining their numerical results directly would not be methodologically sound. It is intended instead as a visual summary of where the literature consistently points: toward broader and more consistent benefit from the combination across glycemic, antioxidant, anti-inflammatory, insulin-signaling and cognitive domains than from either compound alone.



Figure 3. Schematic comparison of reported benefit across domains for curcumin alone, quercetin alone, and the combination.

Two points of caution are worth stating clearly. First, most of the direct combination evidence currently available is preclinical or in vitro. Head-to-head clinical trials comparing curcumin alone, quercetin alone and the combination in diabetic patients with documented cognitive assessment are still rare. Second, synergy in pharmacology has a specific meaning, namely an effect greater than the sum of the individual effects, and this should be distinguished from simple additive benefit, which is what most of the available combination studies actually demonstrate. Both are clinically useful, but the terms should not be used interchangeably when describing the evidence.

Preclinical Evidence

A substantial body of animal research supports the individual and, increasingly, combined use of curcumin and quercetin in models relevant to diabetes-associated metabolic and cognitive dysfunction. Table 1 summarizes a representative set of studies discussed in this review, selected to illustrate the range of models, interventions and outcome measures reported in the recent literature.

Study / Model	Species & Model	Intervention	Key Reported Outcome
Curcumin in diabetes + cerebral hypoperfusion [12]	Rat, high-fat diet + STZ + carotid occlusion	Curcumin, 50 mg/kg, intraperitoneal	Reduced hippocampal damage; suppressed TREM2/TLR4/NF-κB; less apoptosis and pyroptosis
Exercise plus curcumin in T2DM [15]	OLETF rat (spontaneous T2DM model)	Dietary curcumin (5 g/kg diet) plus exercise	Improved glucose homeostasis; better Morris water maze performance; lower IL-6, TNF-α
Quercetin in diabetic neuropathy [6]	STZ-induced diabetic rat	Quercetin, 30–60 mg/kg/day, oral	Improved AMPK/PGC-1α signaling; corrected mitochondrial abnormality
Quercetin in diabetic kidney disease [11]	STZ-induced diabetic rat; HK-2 cells	Quercetin, oral / cell treatment	Inhibited ferroptosis; activated Nrf2; reduced renal tubular damage
Curcumin-quercetin-polydatin combination [21]	In vitro, high-glucose-treated cells	Combined polyphenol treatment	Greater reduction in inflammation and oxidative stress than single compounds
Curcumin-quercetin nanoparticle delivery [20]	In vitro intestinal absorption model	Zein/sodium caseinate co-encapsulated nanoparticles	Nearly two-fold increase in curcumin bioaccessibility and transport rate
Curcumin-quercetin phytosome tablets [17]	Rodent T2DM model	Phytosome-formulated combination tablet	Improved solubility, stability and in vivo antidiabetic response
Curcumin and resveratrol in diabetic Alzheimer model [13]	STZ-induced diabetic rat with Alzheimer features	Curcumin plus resveratrol, oral	Reduced neuronal apoptosis and astrocyte activation; improved histological markers

Several patterns emerge from this body of work. First, streptozotocin-induced and high-fat-diet models remain the dominant experimental approach, providing a reasonably consistent basis for cross-study comparison despite differences in dosing and duration. Second, behavioral testing, most commonly the Morris water maze, is the standard method for assessing cognitive outcomes, and improvements in escape latency and memory retention are reported with reasonable consistency across studies using either compound. Third, biochemical endpoints such as inflammatory cytokines, oxidative stress markers and Nrf2 or AMPK pathway activity are used far more often than direct histological assessment of neurodegeneration, which means conclusions about structural neuroprotection should be treated as provisional pending more detailed morphological studies.

A further observation, relevant to the combination question specifically, is that studies co-administering curcumin and quercetin, whether as a simple mixture, a phytosome formulation or a co-encapsulated nanoparticle system, consistently report either additive or synergistic improvement over single-compound treatment, and none of the studies reviewed reported a combination that performed worse than either compound alone. This is a reassuring, though still limited, signal that the two compounds do not interfere with one another mechanistically.

Clinical Evidence and Translational Considerations

Clinical data specifically addressing the combination of curcumin and quercetin in diabetes-associated cognitive decline remain limited, and this is one of the clearest gaps identified by this review. Most human trial evidence to date has examined the two compounds separately and has generally focused on metabolic rather than cognitive endpoints.

For curcumin, a recent systematic review and meta-analysis of randomized controlled trials evaluating nanocurcumin supplementation in patients with type 2 diabetes found favorable effects on glycemic control and related metabolic markers, though the authors noted considerable heterogeneity in dosing and formulation across the included trials [22]. Cognitive outcomes were not the primary focus of the trials included in that analysis, illustrating how the metabolic and cognitive strands of curcumin research have largely developed on separate tracks.

For quercetin, clinical evidence on metabolic outcomes is somewhat more consistent than its cognitive evidence. A systematic review and meta-analysis of randomized controlled trials found that quercetin supplementation significantly reduced liver enzymes and

inflammatory markers in patients with metabolic dysfunction-associated steatotic liver disease, a condition that shares substantial pathophysiological overlap with type 2 diabetes [10]. In contrast, the largest available randomized trial testing quercetin specifically for cognitive outcomes, conducted in a general adult population rather than a diabetic one, found no significant benefit on memory, psychomotor speed or attention [1]. As discussed in section 5.2, this discrepancy may reflect the fact that quercetin's cognitive benefit, where it exists, is likely to be most relevant in a metabolically compromised, insulin-resistant brain rather than in cognitively healthy adults.

Interest in senolytic and polyphenol combination approaches for age- and disease-related cognitive decline is also growing in adjacent fields. A pilot clinical trial protocol combining quercetin with the senolytic agent dasatinib is currently underway to assess feasibility and safety in older adults with schizophrenia, schizoaffective disorder or treatment-resistant depression, conditions associated with accelerated biological aging [16]. While this trial does not address diabetes directly, it reflects a broader clinical movement toward testing polyphenol combinations for cognitive protection, and its methodology, including safety monitoring protocols for older or medically complex populations, is instructive for future diabetes-focused trial design.

Taken together, the clinical picture at present can be summarized as follows: curcumin and quercetin each have reasonably solid, though not unanimous, human evidence for metabolic benefit in diabetes and related conditions; direct clinical evidence for their combined use is still emerging, mostly from formulation and pharmacokinetic studies rather than outcome-focused trials; and clinical evidence connecting either compound, alone or combined, to measurable cognitive benefit specifically in diabetic patients is essentially absent and represents the most pressing research gap in this field.

Bioavailability, Delivery Systems and Pharmacokinetic Challenges

Poor oral bioavailability is the single most consistently cited barrier to clinical translation for both curcumin and quercetin. Curcumin has extremely low aqueous solubility, undergoes rapid first-pass metabolism through glucuronidation and sulfation, and is cleared from systemic circulation quickly, such that conventional oral dosing achieves only modest plasma concentrations even at high doses [18]. Quercetin faces a similar combination of poor solubility and extensive first-pass metabolism, which limits the amount of active compound that reaches target tissue.

A number of delivery strategies have been developed to address this problem, and several have been tested specifically for curcumin-quercetin co-delivery. Phytosome technology, in which the phytochemical is complexed with phospholipids to improve membrane permeability, has been used to formulate combined curcumin-quercetin tablets, with reported improvements in solubility, stability and in vivo antidiabetic response compared with unformulated compound [17]. Nanoparticle-based co-encapsulation using food-grade proteins such as zein and sodium caseinate has achieved nanoparticle sizes in the range of 174 to 191 nanometers with good dispersibility, high encapsulation efficiency for both compounds, and close to a two-fold increase in curcumin bioaccessibility and intestinal transport [20]. Separately, infinite coordination polymer nanoparticles combining curcumin with the conventional antidiabetic drug metformin have shown high drug encapsulation efficiency and stable performance in diabetic mouse models, illustrating a related strategy of pairing a phytochemical with a standard pharmacological agent rather than with a second phytochemical [19].

Beyond formulation chemistry, delivery to the central nervous system introduces an additional barrier, the blood-brain barrier itself. Nutritional nanoparticle systems designed for brain delivery, particularly smaller particles under 100 nanometers with polyethylene glycol-type surface coatings, have shown improved brain accumulation and neuroprotective effects in preclinical models, though the available data remain limited by methodological heterogeneity and a near-total absence of chronic toxicity data in humans [23].

Figure 4 outlines a translational roadmap for how curcumin-quercetin combination therapy is likely to progress from its current largely preclinical and formulation-focused state toward clinical application, drawing on the general drug development pathway already used for individual phytochemicals such as nanocurcumin.

Figure 4. Translational Roadmap for Curcumin-Quercetin Combination Therapy from Bench to Bedside



Figure 4. Translational roadmap for curcumin-quercetin combination therapy from bench to bedside.

Molecular docking and network pharmacology approaches, which computationally predict how a compound interacts with protein targets before any laboratory work begins, have become a standard first step in this pipeline. Studies applying these methods to curcumin and quercetin individually have identified overlapping hub targets, including AKT1 and several inflammation-related proteins, that are consistent with the mechanistic picture described in section 4 [30,31,33,34]. This computational groundwork, when followed through the full preclinical and clinical pipeline shown in Figure 4, represents the most efficient route toward well-supported, standardized combination therapy.

Safety, Toxicology and Drug Interaction Considerations

Both curcumin and quercetin have long histories of dietary consumption and are generally regarded as safe at commonly studied supplemental doses. Adverse effects reported in clinical trials are typically mild and gastrointestinal in nature, such as bloating or diarrhea, and serious toxicity is rare in the populations studied so far. This safety profile is one of the practical advantages phytochemical combination therapy holds over the addition of another synthetic pharmacological agent, particularly in older diabetic patients who are frequently already managing several medications.

That said, a few caveats deserve mention. Curcumin can mildly inhibit certain cytochrome P450 enzymes and has been associated with reduced iron absorption at high doses, which is relevant for patients also being treated for anemia. Quercetin has demonstrated potential interactions with some anticoagulant and antiplatelet medications in isolated case reports, warranting caution in patients on warfarin or similar agents. Because nanoformulated and phytosome-based preparations can substantially increase systemic bioavailability compared with unformulated compound, the safety data generated using conventional oral dosing cannot be assumed to apply directly to these newer formulations, and separate toxicology and pharmacokinetic evaluation is needed for each delivery platform before it is used clinically [18,19,20]. Long-term human safety data, beyond the duration of typical eight- to twelve-week clinical trials, also remain limited for both compounds and are essentially absent for co-administration specifically.

Challenges and Future Directions

Several obstacles stand between the encouraging preclinical picture described in this review and a clinically validated combination therapy. These challenges, and the research directions most likely to address them, are summarized in Table 2.

Challenge	Why It Matters	Suggested Direction
Poor and variable oral bioavailability	Limits systemic exposure and makes cross-study dose comparison difficult	Standardized phytosome or nanoparticle formulations with published pharmacokinetic profiles
Lack of dedicated combination clinical trials	Most human data comes from single-compound studies	Randomized controlled trials directly comparing monotherapy and combination arms in diabetic patients

Absence of cognitive endpoints in metabolic trials	Cognitive benefit in diabetic patients remains largely unproven in humans	Inclusion of validated cognitive assessment tools in future diabetes-focused trials
Heterogeneous dosing and formulation across studies	Makes meta-analysis and dose-response conclusions difficult	Consensus on standardized dosing ranges for preclinical and early clinical work
Limited chronic safety data for combined and nanoformulated products	Long-term risk profile is not fully established	Extended-duration toxicology and pharmacovigilance studies
Unclear distinction between additive and truly synergistic effects	Overstating synergy could mislead dosing strategy	Formal isobolographic or combination-index analysis in future preclinical work

Looking ahead, three developments seem likely to shape the next phase of research. First, network pharmacology and molecular docking will continue to guide target selection and mechanistic hypothesis generation before laboratory studies begin, as already seen in recent curcumin and quercetin diabetes research [30,31,32,34]. Second, delivery technology will remain a central focus, with phytosome and nanoparticle platforms likely to be tested against a wider range of outcome measures, including direct comparison with unformulated compound in the same study design. Third, and most importantly for the specific focus of this review, there is a clear need for prospective clinical studies that enroll diabetic patients specifically, administer curcumin and quercetin in combination using a bioavailability-enhanced formulation, and assess both metabolic and cognitive outcomes within the same trial. Without this kind of integrated trial design, the metabolic and cognitive evidence bases for these compounds will likely continue to develop along separate paths, as they largely have to date.

Conclusion

Diabetes-associated metabolic dysfunction and diabetes-associated cognitive decline are not independent problems occurring by coincidence in the same patients. They arise from a shared set of molecular disturbances, chiefly oxidative stress, chronic inflammation and impaired insulin and AMPK signaling, that manifest differently depending on the tissue affected. This overlap provides a rational basis for therapies capable of acting on more than one of these shared pathways at once, and curcumin and quercetin, used together rather than separately, fit this description reasonably well based on the evidence reviewed here.

The preclinical evidence for combined curcumin-quercetin therapy is encouraging and growing, with consistent reports of additive or complementary benefit across glycemic, antioxidant, anti-inflammatory and cognitive outcome measures, and delivery technologies such as phytosomes and co-encapsulated nanoparticles are already improving the practical usability of both compounds. Clinical evidence, however, remains at an earlier stage, particularly for cognitive outcomes, and the field would benefit substantially from trials that assess metabolic and cognitive endpoints together in diabetic populations, using standardized, bioavailability-enhanced formulations.

For clinicians and researchers working in veterinary and human pharmacology alike, the message from this body of work is a cautiously optimistic one. Combination phytochemical therapy is unlikely to replace established antidiabetic pharmacology, but it holds real promise as a low-toxicity adjunct approach, particularly for the cognitive and behavioral dimension of diabetes that conventional glucose-lowering therapy does not directly address. Realizing that promise will depend on closing the gap between the mechanistic and preclinical evidence summarized in this review and the well-designed human trials that are still needed to confirm it.

References

International Diabetes Federation. IDF Diabetes Atlas, 11th ed. Brussels: International Diabetes Federation; 2025. Available from: https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/

International Diabetes Federation. Diabetes facts and figures. 2025. Available from: https://idf.org/about-diabetes/diabetes-facts-figures/

Teufel F, Orgutsova K, Genitsaridi I, Carrillo-Larco RM, Varghese JS, Marcus ME, et al. Global, regional, and national estimates of undiagnosed diabetes in adults: findings from the 2025 IDF Diabetes Atlas. Diabetes Care. 2026;49(3):490-496. doi:10.2337/dc25-2583

Not one-size-fits-all: diabetes in south Asia. Lancet Reg Health Southeast Asia. 2025. doi:10.1016/j.lansea.2025.100694

Ganesan K, Xu B, Deepa M. Curcumin and its derivatives: the potential as therapeutic agents in diabetes and its complications. Phytother Res. 2023;37(2):345-364.

Zhang Q, Song W, Zhao B, Xie J, Sun Q, Shi X, et al. Quercetin attenuates diabetic peripheral neuropathy by correcting mitochondrial abnormality via activation of AMPK/PGC-1α pathway in vivo and in vitro. Front Neurosci. 2021;15:636172. doi:10.3389/fnins.2021.636172

Therapeutic potential of quercetin in the management of type-2 diabetes mellitus. PMC9409999. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9409999/

Quercetin in metabolic diseases: mechanisms, therapeutics, and multidimensional frontiers. Front Endocrinol. 2026. doi:10.3389/fendo.2026.1800322

Potential of quercetin as a promising therapeutic agent against type 2 diabetes. Molecules. 2025;30(15):3096. doi:10.3390/molecules30153096

Jin D, Jin S, Zhou T, Sheng G, Gao P, Li G. Effects of quercetin on metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. Food Sci Nutr. 2025. doi:10.1002/fsn3.71358

Zhang L, Wang X, Chang L, Ren Y, Sui M, Fu Y, et al. Quercetin improves diabetic kidney disease by inhibiting ferroptosis and regulating Nrf2 in streptozotocin-induced diabetic rats. Ren Fail. 2024;46(1). doi:10.1080/0886022X.2024.2327495

Curcumin protects against cognitive impairments in a rat model of chronic cerebral hypoperfusion combined with diabetes mellitus by suppressing neuroinflammation, apoptosis, and pyroptosis. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1567576921000588

Protective effects of curcumin and resveratrol on neurodegeneration and cognitive dysfunction in a streptozotocin-induced Alzheimer rat model. Sci Rep. 2026. Available from: https://www.nature.com/articles/s41598-026-48216-9

Targeting cognitive aging with curcumin supplementation: a systematic review and meta-analysis. 2025. Available from: https://www.sciencedirect.com/science/article/pii/S2274580725001918

Exercise and curcumin in combination improves cognitive function and attenuates ER stress in diabetic rats. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284733/

Schweiger A, Diniz B, Nicol G, Schweiger J, Dasklakis-Perez AE, Lenze EJ, et al. Protocol for a pilot clinical trial of the senolytic drug combination dasatinib plus quercetin to mitigate age-related health and cognitive decline in mental disorders. F1000Res. 2025. doi:10.12688/f1000research.151963.2

Formulation, optimization, and in vivo evaluation of curcumin-quercetin phytosome tablets for the management of type 2 diabetes mellitus. J Pharm Innov. 2026. doi:10.1007/s12247-026-10597-9

Harnessing the potential of curcumin and nano-curcumin in diabetes: a detailed review. Available from: https://www.sciencedirect.com/science/article/abs/pii/S2213434426000459

Sun S, Hou X, Li K, Huang C, Rong Y, Bi J, et al. Curcumin and metformin infinite coordination polymer nanoparticles for combined therapy of diabetic mice via intraperitoneal injections. J Funct Biomater. 2024;15(12):388. doi:10.3390/jfb15120388

Li Y, Shi R, Xu Z, Huang T, Wang S, Sang Y, et al. Nanoparticles for synergistic delivery of curcumin and quercetin based on zein and sodium caseinate: preparation, characterization, and intestinal absorption. Foods. 2026;15(2):225. doi:10.3390/foods15020225

Matacchione G, Valli D, Silvestrini A, Giuliani A, Sabbatinelli J, Giordani C, et al. Curcumin, polydatin and quercetin synergistic activity protects from high-glucose-induced inflammation and oxidative stress. Antioxidants. 2022;11(6):1037. doi:10.3390/antiox11061037

Ghoflchi S, et al. Evaluating the effects of nanocurcumin supplementation in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Endocrinol Diabetes Metab. 2026. doi:10.1002/edm2.70242

Nutritional nanoparticles as neuroprotection vehicles. Res Diabetic Stud. 2025;21(S9). Available from: https://diabeticstudies.org/index.php/RDS/article/download/652/537

Khan A, Agouni A. Network pharmacology integrated with quantum-polarized ligand docking and molecular simulation revealed the anti-diabetic potential of curcumin. ChemistrySelect. 2024;9:e202402379. doi:10.1002/slct.202402379

Integrating network pharmacology, molecular docking and experimental validation to explore the pharmacological mechanisms of quercetin against diabetic wound. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11539386/

Network pharmacology and molecular docking approaches in antidiabetic herbal drug research. Available from: https://www.ijpsjournal.com/article/Network+Pharmacology+and+Molecular+Docking+Approaches+In+Antidiabetic+Herbal+Drug+Research

Network pharmacology, molecular docking and molecular dynamics studies to predict the molecular targets and mechanisms of action of Melissa officinalis phytoconstituents in type-2 diabetes mellitus. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12473937/

Mechanistic investigation of quercetin in the management of diabetic foot ulcer by network pharmacology and molecular docking. Available from: https://www.sciencedirect.com/science/article/pii/S2667142524000186

Ma X, Hao C, Yu M, Zhang Z, Huang J, Yang W. Investigating the molecular mechanism of quercetin protecting against podocyte injury to attenuate diabetic nephropathy through network pharmacology, microarray data analysis, and molecular docking. J Diabetes Res. 2022. doi:10.1155/2022/7291434

Quercetin (supplement): cognitive vitality report. Alzheimer's Drug Discovery Foundation. 2025. Available from: https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Quercetin_(supplement).pdf